Participated · Series C · May 2018

NeuroVision Imaging develops noninvasive diagnostic solutions and blood-based biomarkers aimed at early detection and monitoring of Alzheimer’s disease and related dementias. The company focuses on measuring beta-amyloid protein complexes in blood as a potential screening tool that could identify disease decades before symptoms appear. Current studies are led by Leyla Anderson, MD, PhD, VP of Biomarker Development, and Blaine Roberts, PhD, and will validate recent findings using blood samples from the Australian Imaging and Biomarker Lifestyle study (AIBL). NeuroVision says its technology can measure protein complexes with sensitivity and specificity above industry standards and intends these tools to improve clinical trials, treatment monitoring, and enable earlier interventions. The company was formed in 2010 and is headquartered in Sacramento, California, and its team has experience in fluid biomarkers, imaging, and data science. The article does not disclose revenue or other operating metrics. NeuroVision Imaging is developing digital imaging and diagnostic solutions to identify retinal pathology related to Alzheimer’s disease. Its core product is a low-cost, noninvasive eye imaging system that measures retinal autofluorescence to detect amyloid beta (Aβ) plaque in the eye. The company has developed proprietary image-processing and machine-learning algorithms to quantify eye pathology as an assessment of amyloid status in the central nervous system. NeuroVision holds the exclusive worldwide license to the underlying technology, which was discovered by a team at Cedars‑Sinai Medical Center. The company says its goal is to create an accessible product to help identify people who may be affected by Alzheimer’s and is pursuing validation and regulatory approval. NeuroVision was formed in 2010 and is led by CEO Steven Verdooner. NeuroVision Imaging develops a proprietary retinal imaging test for early detection and monitoring of Alzheimer’s disease that combines a retinal imaging system with a high-bioavailability curcumin formulation. The company’s founding team, under Keith L. Black, M.D., and Maya Koronyo-Hamaoui, Ph.D., validated noninvasive retinal imaging in transgenic mouse models and human cadaver studies. NeuroVision holds the exclusive worldwide license to the technology from Cedars-Sinai and is led by CEO Steven Verdooner. Commercialization plans call for establishing a simple eye test as a noninvasive, high-resolution optical standard of care for AD diagnosis, prognosis assessment, and monitoring response to therapies. The company intends to use new funding to advance validation and pursue regulatory approval for its retinal imaging technology.